SPONSOR
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 1, Phase 2, Phase 1
Conditions studied: Non-alcoholic SteatohepatitisAdvanced Solid TumorBiliary Tract CancerAdvanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Non-alcoholic Steatohepatitis, Advanced Solid Tumor, Biliary Tract Cancer, Advanced Cancer.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
How many clinical trials has Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., of which 4 are actively recruiting participants. These trials cover conditions including Non-alcoholic Steatohepatitis, Advanced Solid Tumor, Biliary Tract Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. research focus on?
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. clinical trials span Non-alcoholic Steatohepatitis, Advanced Solid Tumor, Biliary Tract Cancer, Advanced Cancer. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. clinical trial?
To participate in a Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT06569524 Phase 2
Recruiting
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Steatohepatitis
NCT06825494 Phase 1, Phase 2
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
Advanced Solid Tumor
NCT06431490 Phase 1, Phase 2
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
NCT06188624 Phase 1
Recruiting
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Advanced Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology